Payment overview · 2025
General Payments
$22.91
1 reported records · 1 companies
Healthcare provider profile · identity verified
Daniel Mandel, DO
Allopathic & Osteopathic Physicians|Internal Medicine · PHILADELPHIA, PA · NPI 1144783465
Verified facts
What the public records show
CMS Open Payments records show Daniel Mandel, DO received $22.91 in general payments during 2025 across 1 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.91 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $22.91 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 609 | 213 |
| Lisinopril | Lisinopril | 322 | 105 |
| Gabapentin | Gabapentin | 316 | 116 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 274 | 88 |
| Omeprazole | Omeprazole | 249 | 91 |
| Metformin Hcl | Metformin Hcl | 219 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 78 |
| Trazodone Hcl | Trazodone Hcl | 205 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 53 |
| Losartan Potassium | Losartan Potassium | 176 | 59 |
| Diclofenac Sodium | Diclofenac Sodium | 174 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 174 | 47 |
| Metformin Hcl Er | Metformin Hcl | 173 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 45 |
| Furosemide | Furosemide | 129 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 43 |
| Jardiance | Empagliflozin | 127 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 43 |
| Ozempic | Semaglutide | 117 | 29 |
| Farxiga | Dapagliflozin Propanediol | 115 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 113 | 46 |
| Tramadol Hcl | Tramadol Hcl | 110 | 39 |
| Trulicity | Dulaglutide | 109 | 25 |
| Carvedilol | Carvedilol | 107 | 34 |
| Famotidine | Famotidine | 107 | 36 |
| Ibuprofen | Ibuprofen | 102 | 50 |
| Mirtazapine | Mirtazapine | 102 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 31 |
| Montelukast Sodium | Montelukast Sodium | 98 | 24 |
| Simvastatin | Simvastatin | 86 | 28 |
| Alendronate Sodium | Alendronate Sodium | 83 | 28 |
| Meloxicam | Meloxicam | 83 | 30 |
| Sertraline Hcl | Sertraline Hcl | 80 | 24 |
| Meclizine Hcl | Meclizine Hcl | 76 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 32 |
| Eliquis | Apixaban | 60 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 20 |
| Ezetimibe | Ezetimibe | 59 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 16 |
| Alprazolam | Alprazolam | 47 | 14 |
| Clotrimazole | Clotrimazole | 45 | 19 |
| Glipizide Er | Glipizide | 45 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 17 |
| Ammonium Lactate | Ammonium Lactate | 42 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Colchicine | Colchicine | 41 | 13 |
| Finasteride | Finasteride | 41 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 13 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Ketoconazole | Ketoconazole | 39 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 11 |
| Alcohol Pads | Alcohol Antiseptic Pads | 37 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 12 |
| Allopurinol | Allopurinol | 36 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Naproxen | Naproxen | 34 | 16 |
| Incruse Ellipta | Umeclidinium Bromide | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 29 | 11 |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Prednisone | Prednisone | 29 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | 14 |
| Estradiol | Estradiol | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 25 |
| Nitroglycerin | Nitroglycerin | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 23 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | 12 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 23 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | 13 |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Tacrolimus | Tacrolimus | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $22.91 · 1 records | PFIZER INC. | ELIQUIS, NURTEC ODT, PAXLOVID | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error